Preclinical models demonstrate that BGB-21447 exhibits superior potency against Venetoclax-resistant hematologic malignancies, suggesting new treatment options.
Key Points
Characterize the effectiveness of BGB-21447, a next-generation Bcl-2 inhibitor, against Venetoclax resistance in hematologic cancers.
Conducted a preclinical evaluation of BGB-21447 in hematologic cancer cell lines and xenograft models.
Assessed drug potency by measuring IC50 values compared to Venetoclax.
Analyzed intrinsic apoptosis markers such as cleaved caspase levels and phosphatidylserine externalization.
Performed pharmacokinetic and pharmacodynamic studies to evaluate exposure-response relationships.
BGB-21447 demonstrated ≥121-fold selectivity for Bcl-2 over other Bcl family proteins.
Achieved lower IC50 values than Venetoclax across multiple cell lines and Bcl-2 mutant models.
Effectively induced intrinsic apoptosis characterized by caspase activation and cellular changes.
Showed substantial antitumor efficacy in Venetoclax-insensitive models without significant toxicity.